American Gene Technologies International (AGT) was founded with the mission to develop innovative gene therapies aimed at curing severe diseases such as HIV and cancer. The company leverages cutting-edge genetic technologies to create long-term value for patients, society, investors, and donors. AGT's product pipeline includes therapies for HIV, phenylketonuria (PKU), and various cancers, focusing on rapid drug development and the efficiency of their platform technologies.
Notable figures affiliated with AGT include its leadership team, which comprises experts in gene therapy and biotechnology. The company has garnered significant attention for its HIV cure clinical trial, which has the potential to revolutionize treatment for one of the world's most challenging epidemics. AGT's achievements in advancing gene therapy have positioned it as a key player in the biotech industry, with a growing impact on medical research and patient outcomes.
